Rigosertib for RDEB-SCC

NCT03786237 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Epidermolysis Bullosa Dystrophica
Squamous Cell Carcinoma

Interventions

DRUG: Rigosertib Oral Capsules / Rigosertib Intravenous

Sponsor

Prof. Johann Bauer